Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New results expand Velcade potential
Using the 9th International Conference of Malignant Lymphoma as its forum, Millennium has reported achieving positive outcomes in investigations of Velcade into patients with indolent and mantle cell
Using the 9th International Conference of Malignant Lymphoma as its forum, Millennium has reported achieving positive outcomes in investigations of Velcade into patients with indolent and mantle cell
GSK656398 is an inhaled, long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines
The exchange is designed to create an electronic health record of both inpatient and ambulatory data. This data is then delivered to all members of a patient’s care
The negative out come has sent shares in skin treatment developer Connetics down by 26% and forced the company to cut 2005 financial forecasts. The failure of Velac
The findings show that NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection) can be used effectively once and up to three times daily
The free service is the brainchild of the Partnership for Safe Medicines, a coalition of patient, physician, pharmacist, university, industry and professional organizations. It works by monitoring government
The agreement comes after Lorus met with the FDA on May 25, 2005 to discuss the chemistry, manufacturing, controls (quality) and non-clinical data packages that it plans to
Following the acquisition, Cephalon will assume the worldwide marketing, sales and development of Trisenox (arsenic trioxide) injection, a product that had worldwide sales of $26.6 million in 2004.
The hospitals will begin collecting blood samples from consenting patients in disease areas that coincide with ChondroGene’s primary areas of interest – cancer, cardiovascular disease, central nervous system
During preclinical trials of the toxin, now called ACV1, researchers from Metabolic Pharmaceuticals found it not only to be effective in treating pain in animal models of post-surgical